Mirtazapine Sandoz 45

Mirtazapine, the active ingredient in Mirtazapine Sandoz 45, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as a 45 mg tablet for oral use. It treats major depressive disorder in adults. GNH USA supplies Mirtazapine Sandoz 45 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is a NaSSA antidepressant used in the management of depressive disorders.

Major depressive disorder: reduces depressive symptoms and improves overall mood. Depression with insomnia: promotes sleep onset and improves sleep quality. Depression with anxiety: alleviates anxiety symptoms that accompany depressive episodes.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness or light‑headedness - Blurred vision

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Leukopenia - Seizures - Suicidal thoughts or behavior - Severe hypersensitivity reactions (rash, angioedema) - Hepatotoxicity

Before initiating therapy, clinicians should consider several safety aspects. - Assess hepatic function: adjust use in patients with liver impairment. - Monitor weight and appetite: watch for significant gain. - Evaluate for suicidal ideation: especially during early treatment. - Use caution in cardiovascular disease: watch for orthostatic hypotension. - Avoid abrupt discontinuation: taper to reduce withdrawal symptoms. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increased mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine): reduced efficacy. - Anticholinergic agents: heightened anticholinergic burden. - Other serotonergic drugs (e.g., SSRIs, SNRIs): potential serotonin syndrome.